ZTI-Technologies is a pure IP holding company owning three licensable β-titanium platforms covering a $43.1B addressable market — medical, aerospace, defense, and marine.
Three granted patent families (US · EU · India), three USPTO provisional applications filed May 18, 2026, and one normative position in ASTM WK84537 — voted 96.36%.
β-Ti-19Nb-14Zr alloy with 14 GPa elastic modulus. BIC 95% in vivo. ×26 corrosion resistance vs Ti-6Al-4V. The benchmark replacement alloy for CoCrMo (banned EU May 2025).
Thermo-mechanical auto-locking dental implant with TPMS lattice architecture. Three-level locking mechanism. +219% bone-implant contact surface vs conventional implants.
Ti6Al4V + 1wt% nYSZ nanocomposite. 844 MPa HCF endurance after HIP — exceeds wrought Ti-6Al-4V. Superior fatigue-to-impurity ratio. EIGA-compatible powder route.
Ti6Al4V-(10-35)Zr. AM-compatible evolution of Ti-6Al-4V. Same machines, same workflows. Five industrial verticals: Aerospace · Gas Turbines · Marine · Defense · Sport.
Optimized EIGA atomization process for ZTM14N and T20Z powders. >80% yield in 15–45µm fraction. Crucible-free. Validated at industrial scale: Eckart GmbH (DE) + China.
AI-driven OPG→CNN→ISQ→TPMS→SLM pipeline. Dilated multi-scale CNN. r=0.87 on 320 patients. Pre-operative ISQ prediction — world first. Structural incompatibility with Medimaps variogram methods.
Biomimetic medical implants with the lowest modulus AM alloy on the market. CoCrMo replacement platform for a market in forced transition since May 2025.
AM-compatible evolution of Ti-6Al-4V. Same machines, same certification base. Drop-in upgrade for aerospace, turbines, marine, defense, and high-performance sport.
No competitor simultaneously holds biological, chemical, and mechanical validation — all peer-reviewed and independently verified.
Access the ZTI-Technologies investor data room. NDA-gated. Full IP portfolio, valuation methodology, and partnership terms available.